Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
The combination of cyclophosphamide, cis-platinum, and adriamycin has been evaluated in the Nb tumor model system. Triple drug therapy has resulted in marked reduction in tumor volume (P less than 0.01), as well as decreased number of metastases (P less than 0.01). Combination chemotherapy has reduced the metastatic rate, increased complete tumor regression, and reduced the final tumor volume. The androgen insensitive tumor of Nb Pr A.I.-II was evaluated with combinations of BCNU and adriamycin in three cycles. The final tumor volume when compared to controls was significant for all of the agents evaluated (P less than 0.01). A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin. The acid phosphatase content of the treatment group's tumors, when compared to controls was significant with BCNU treatment only.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000818:Animals; D002330:Carmustine / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage*; D008297:Male; D009362:Neoplasm Metastasis; D009365:Neoplasm Regression, Spontaneous / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D004338:Drug Combinations; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D002330:Carmustine